PMID: 7017729Apr 1, 1981Paper

Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C

Proceedings of the National Academy of Sciences of the United States of America
C T Esmon, W G Owen

Abstract

Perfusion of the myocardium with protein C in the presence of thrombin (EC 3.4.21.5) elicits a potent anticoagulant activity, which is identified as activated protein C on the basis of synthetic substrate hydrolysis and anticoagulant properties. The rate of activated protein C formation during the transit through the myocardium is at least 20,000 times that of thrombin-catalyzed activation of protein C in the perfusion solution. The capacity of the heart to activate protein C is maintained for at least 1 hr when thrombin is present in the perfusate, but decays (half-life approximately 30 min) once thrombin is omitted. Addition of diisopropyl-phospho-thrombin increases this decay rate more than 10-fold. Coperfusing diisopropylphospho-thrombin with active thrombin lowers the amount of protein C activation in the myocardium. Cultured monolayers of human endothelium enhance the rate of thrombin-catalyzed protein C activation. As with myocardium, the activation rate is inhibited by including diisopropylphospho-thrombin in the medium. It is proposed that the surface of vascular endothelium provides a cofactor that enhances the rate of protein C activation by thrombin.

Citations

Jan 1, 1996·Journal of Clinical Laboratory Analysis·H RinnoY Tomino
Sep 1, 1993·Protein Science : a Publication of the Protein Society·R M MestersJ H Griffin
Jan 1, 1997·Protein Science : a Publication of the Protein Society·A J GaleJ H Griffin
Jan 1, 1984·Cancer Metastasis Reviews·G J Gasic
Aug 1, 1986·Molecular and Cellular Biochemistry·T H Carlson
Jan 1, 1995·Archives of Dermatological Research·T KadonoK Takehara
Feb 1, 1996·Annals of Hematology·H Y MukaiT Abe
Nov 1, 1988·Biulleten' eksperimental'noĭ biologii i meditsiny·E F Luk'ianenkoS M Strukova
Mar 1, 1997·Virchows Archiv : an International Journal of Pathology·E TolnayK M Müller
Aug 9, 2011·Seminars in Immunopathology·Charles T Esmon
Mar 20, 2012·Brain Tumor Pathology·Hitoshi YamahataKazunori Arita
Aug 9, 1991·Brain Research·V L WongM Fisher
Nov 30, 1987·Clinica Chimica Acta; International Journal of Clinical Chemistry·D K Strickland, C M Kessler
Nov 30, 1987·Clinica Chimica Acta; International Journal of Clinical Chemistry·C M Kessler, D K Strickland
Oct 16, 1989·Clinica Chimica Acta; International Journal of Clinical Chemistry·K SuzukiM Kita
Mar 1, 1994·Clinica Chimica Acta; International Journal of Clinical Chemistry·H ShimanoN Yamada
Jun 1, 1995·European Journal of Obstetrics, Gynecology, and Reproductive Biology·J BontisK Tagou
Feb 15, 1987·Thrombosis Research·M D Burdick, R G Schaub
Jun 1, 1996·Thrombosis Research·P MarckmannJ Jespersen
Sep 1, 1996·Thrombosis Research·R SalteO R Odegaard
Jan 1, 1983·Molecular Aspects of Medicine·S Elödi, P Elödi
Jan 1, 1985·Molecular Aspects of Medicine·A B Malik, S K Lo
Nov 20, 1993·Lancet·A GruberJ H Griffin
Jan 1, 1994·Pharmacology & Therapeutics·P Sargeant, S O Sage
Jul 16, 1986·Biochimica Et Biophysica Acta·K SuzukiS Hashimoto
Apr 17, 2004·Journal of Immunological Methods·Michael Wolfgang Josef Boehme, Wolfgang Stremmel
Apr 6, 2004·Maturitas·Charles T Esmon
Mar 22, 2005·Pulmonary Pharmacology & Therapeutics·Ming-Yuan JianKeishi Kubo
Oct 6, 2000·Clinica Chimica Acta; International Journal of Clinical Chemistry·Y AsoY Takemura
Sep 17, 1999·Atherosclerosis·F Pérez-JiménezJ M Ordovás

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.